590 related articles for article (PubMed ID: 34497203)
1. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
2. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R; Bazarbachi AH; Bazarbachi A; Malard F; Harousseau JL; Mohty M
Blood Cancer J; 2021 May; 11(5):97. PubMed ID: 34006856
[TBL] [Abstract][Full Text] [Related]
7. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
8. Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment.
Cherico AS; Rizvi A; Jayakrishnan T; Mewawalla P
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35817492
[TBL] [Abstract][Full Text] [Related]
9. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
10. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.
Witteles RM; Liedtke M
JACC CardioOncol; 2019 Sep; 1(1):117-130. PubMed ID: 34396169
[TBL] [Abstract][Full Text] [Related]
11. Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.
Maurer MS; Dunnmon P; Fontana M; Quarta CC; Prasad K; Witteles RM; Rapezzi C; Signorovitch J; Lousada I; Merlini G
Circ Heart Fail; 2022 Jun; 15(6):e009038. PubMed ID: 35331001
[TBL] [Abstract][Full Text] [Related]
12. T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
Wang Y; Xu L; Zhao W; Chen X; Wen L; Duan W; Yu XJ; De Zhou F; Liu Y; Hao J; Huang X; Lu J; Ge Q
Clin Transl Med; 2021 Nov; 11(11):e582. PubMed ID: 34845849
[TBL] [Abstract][Full Text] [Related]
13. Bad players in AL amyloidosis in the current era of treatment.
Kreiniz N; Gertz MA
Expert Rev Hematol; 2023 Jan; 16(1):33-49. PubMed ID: 36620914
[TBL] [Abstract][Full Text] [Related]
14. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
Del Giudice ML; Galimberti S; Buda G
Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplant for Al amyloidosis.
Roy V
Bone Marrow Res; 2012; 2012():238961. PubMed ID: 22675637
[TBL] [Abstract][Full Text] [Related]
16. Update on treatment of light chain amyloidosis.
Mahmood S; Palladini G; Sanchorawala V; Wechalekar A
Haematologica; 2014 Feb; 99(2):209-21. PubMed ID: 24497558
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies in Light Chain Amyloidosis.
Milani P; Merlini G; Palladini G
Kidney Int Rep; 2018 May; 3(3):530-541. PubMed ID: 29854961
[TBL] [Abstract][Full Text] [Related]
18. AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects:
Wechalekar AD; Fontana M; Quarta CC; Liedtke M
JACC CardioOncol; 2022 Nov; 4(4):427-441. PubMed ID: 36444232
[TBL] [Abstract][Full Text] [Related]
19. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
Ravichandran S; Law S; Mahmood S; Wisniowski B; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Leukemia; 2022 Apr; 36(4):1180-1184. PubMed ID: 34987193
[No Abstract] [Full Text] [Related]
20. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
Wang J; Li J; Zhong L
Blood Rev; 2024 Apr; ():101207. PubMed ID: 38692939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
